A clinical setback dominated the health and biotech session, as AstraZeneca shed more than 7% after its Phase III CARDIO-TTRansform trial of Wainua in heart disease failed to meet its primary endpoint, the most significant event in an otherwise deal- and financing-focused day for the sector.